OSUR OraSure Technologies Inc.

OraSure Technologies to Present at the UBS Virtual Global Healthcare Conference

OraSure Technologies to Present at the UBS Virtual Global Healthcare Conference

BETHLEHEM, Pa., May 15, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the UBS Virtual Global Healthcare Conference.  The conference will be simultaneously webcast over the Internet.

Dr. Tang is scheduled to speak on May 20, 2020, at approximately 10:50 AM Eastern Standard Time (7:50 AM Pacific Time).  Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, and clicking on the Investor Info link.  A replay of the webcast will be available on OraSure Technologies’ web site for seven days.  Alternatively, you can access the live webcast of the presentation via the following link:

About OraSure Technologies

OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries DNA Genotek, Diversigen, CoreBiome (now operating under the Diversigen brand) and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit .

Company contacts:

Roberto CucaJeanne Mell
Chief Financial OfficerVP Corporate Communications
610-882-1820484-353-1575

EN
15/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OraSure Technologies Inc.

 PRESS RELEASE

OraSure Announces Second Quarter 2025 Financial Results

OraSure Announces Second Quarter 2025 Financial Results BETHLEHEM, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2025. “Our Q2 results were consistent with our expectations. We are making significant progress on our initiatives to expand our product portfolio, including launching our novel blood collection device for proteomic research in July. We are also staying closely aligned with our custome...

 PRESS RELEASE

OraSure Appoints Anne Messing as Chief Commercial Officer

OraSure Appoints Anne Messing as Chief Commercial Officer BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and tra...

 PRESS RELEASE

OraSure to Announce Second Quarter 2025 Financial Results and Host Ear...

OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at . Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webca...

 PRESS RELEASE

OraSure Launches Novel Blood Collection Device for Proteomic Research

OraSure Launches Novel Blood Collection Device for Proteomic Research The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research BETHLEHEM, Pa., July 10, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the launch of its HEMAcollect™●PROTEIN product to meet the evolving needs of proteomic researchers. The product, developed by OTI subsidiary DNA Genotek, is an evacuated blood colle...

 PRESS RELEASE

OraSure Announces First Quarter 2025 Financial Results

OraSure Announces First Quarter 2025 Financial Results BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2025. “Our Q1 results were consistent with our expectations. Our customers continue to demonstrate their preference for our differentiated products in delivering on their important health objectives, even while uncertainty remains elevated related to government funding sources for some ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch